Research programme: transglutaminase inhibitors - Horizon Pharma

Drug Profile

Research programme: transglutaminase inhibitors - Horizon Pharma

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Niigata University of Pharmacy and Applied Life Sciences; Weizmann Institute of Science
  • Developer Horizon Pharma
  • Class
  • Mechanism of Action Transglutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Huntington's disease; Neurological disorders

Most Recent Events

  • 01 Mar 2014 Development is ongoing for Huntington's disease and Neurological disorders in USA
  • 02 Jun 2010 Early research in Huntington's disease in USA (unspecified route)
  • 02 Jun 2010 Early research in Neurological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top